Intermediate for Afatinib. Afatinib (trade name: Gilotrif) is an irreversible covalent inhibitor of the receptor tyrosine kinases epidermal growth factor receptor (EGFR) and erbB-2 (HER2) for the treatment of patients with distinct types of metastatic (EGFR mutation positive) non-small cell lung carcinoma (NSCLC). Afatinib has been approved by the U.S Food and Drug Administration on July 12, 2013.

Specifications

Product Name:                  N-(3-Chloro-4-fluorophenyl)-6-nitro-7-(phenylsulfonyl)quinazolin-4-amine

Synonyms:                         N/A

CAS Number:                     945553-94-6

Molecular Weight:            458.8506

Molecular Formula:          C20H12ClFN4O4S

Purity (HPLC):                     ≥95%

Shipping Conditions:         Room temperature.

Storage Conditions:           Refrigerated.

Regulatory Statement:      For Research Use Only.

SMILES:                               [O-][N+](=O)c1cc2c(ncnc2cc1S(=O)(=O)c1ccccc1)Nc1ccc(c(c1)Cl)F